%0 Journal Article %A Ulrich Broeckel %A M. Anwar Iqbal %A Brynn Levy %A Nikhil Sahajpal %A Peter L. Nagy %A Gunter Scharer %A Aaron D. Bossler %A Vanessa Rodriguez %A Aaron Stence %A Cindy Skinner %A Steven A Skinner %A Ravindra Kolhe %A Roger Stevenson %T Multisite Study of Optical Genome Mapping of Retrospective and Prospective Constitutional Disorder Cohorts %D 2022 %R 10.1101/2022.12.26.22283900 %J medRxiv %P 2022.12.26.22283900 %X Several medical societies including the American College of Medical Genetics and Genomics, the American Academy of Neurology, and the Association of Molecular Pathology recommend chromosomal microarray (CMA) as the first-tier test in the genetic work-up for individuals with neurodevelopmental disorders such as developmental delay and intellectual disability, autism spectrum disorder, as well as other disorders suspected to be of genetic etiology. Although CMA has significantly increased the diagnostic yield for these disorders, limitations in the technology preclude detection of certain structural variations in the genome and requires reflexing to other cytogenomic and molecular methods. Optical genome mapping (OGM) is a high-resolution technology that utilizes ultra-high molecular weight DNA, fluorescently labeled at a hexamer motif found throughout the genome, to create a barcode pattern, analogous to G-banded karyotyping, that can detect all classes of structural variations at very high resolution by comparison to a reference genome.A multisite study, partially published previously, with a total of n=1037 datapoints was conducted and showed 99.6% concordance between OGM and standard-of-care (SOC) testing for completed cases. The current phase of this study included cases from individuals with suspected genetic conditions referred for cytogenomic testing in a prospective postnatal cohort (79 cases with OGM and SOC results) and a retrospective postnatal cohort (262; same criteria). Among these cohorts were an autism spectrum disorder cohort (135) group with negative or uninformative results on previous testing (72). Prospective cases referred for CMA were included in this study as an unbiased comparison, OGM results show 100% concordance with variants of uncertain significance, pathogenic variants, and likely pathogenic variants reported by CMA other SOC and found reportable variants in an additional 10.1% of cases. Among the autism spectrum disorder cohort, OGM found reportable variants in an additional 14.8% of cases. Based on this demonstration of the analytic validity and clinical utility of OGM by this multi-site assessment, and considering clinical diagnostics often require iterative testing for detection and diagnosis in postnatal constitutional disorders, OGM should be considered as a first-tier test for neurodevelopmental disorders and/or suspicion of a genetic disease.Competing Interest StatementRES is a consultant of Bionano Genomics. RK has received honoraria, and/or travel funding, and/or research support from Illumina, Asuragen, QIAGEN, Perkin Elmer Inc, Bionano Genomics, Agena, Agendia, PGDx, Thermo Fisher Scientific, Cepheid, and BMS. All other authors have no relevant disclosures.Funding StatementFunding for this study was provided in part by Bionano Genomics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB20212956 (wcg IRB) Bionano Genomics Inc., San Diego, CA, USA IRB-STU: 1814013 Medical College of Wisconsin, Milwaukee, WI, USA IRBSTUDY00007572: OGM Postnatal Study University of Rochester Medical Center, Rochester, NY, USA IRB AAAT9083 Columbia University Irving Medical Center, New York, NY, USA IRB Pro00085001 (Self Regional Healthcare) Greenwood Genetic Center, Greenwood, SC, USA IRB A 00000150 (HAC IRB 611298) Medical College of Georgia, Augusta University, Augusta, GA, USA I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOGM datasets are deidentified, stored, and available by request to the corresponding authors. Details of variant calls are provided in the supplementary tables. %U https://www.medrxiv.org/content/medrxiv/early/2022/12/31/2022.12.26.22283900.full.pdf